Tartaglia Gianluca Martino, Poli Pier Paolo, Connelly Stephen Thaddeus, Maiorana Carlo, Farronato Davide, Taschieri Silvio
Department of Biomedical, Surgical and Dental Sciences, University of Milan, 20122 Milan, Italy.
Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, 20122 Milan, Italy.
Materials (Basel). 2021 May 11;14(10):2479. doi: 10.3390/ma14102479.
(1) Background: The purpose of the present study was to retrospectively evaluate and compare the outcome of two sinus augmentation grafting protocols using a xenograft or blood clot alone over a 72-month follow-up. (2) Methods: Patients who received simultaneous lateral sinus floor augmentation and implant placement were included. Subjects were divided into two groups according to the grafting material, namely xenograft or blood clot, and into sub-groups based on the residual alveolar bone height (RABH) below the maxillary sinus, namely 4 to 6 mm or >6 mm. Kaplan-Meier survival estimates were calculated for each material group and for each sub-group at 1, 3, and 6 years. (3) Results: In total, 289 implants inserted in 136 patients with a one-stage procedure were considered. A total of 35 failures were registered. Overall survival rates were 94.2% for xenograft and 85.9% for blood clot alone at 1 year, 91.1% and 81.6% at 3 years, and 91.1% and 78.7% at 6 years. (4) Conclusions: In patients with 4-6 mm RABH, graftless interventions exploiting blood clot alone were not as successful as those using xenograft. When the RABH is low, sinus floor augmentation associated with grafting materials should be preferred whenever possible.
(1) 背景：本研究旨在回顾性评估和比较两种鼻窦增高移植方案的结果，这两种方案分别是单独使用异种移植物或血凝块，并进行72个月的随访。(2) 方法：纳入接受同期外侧鼻窦底增高和种植体植入的患者。根据移植材料将受试者分为两组，即异种移植物组或血凝块组，并根据上颌窦下方的剩余牙槽骨高度（RABH）分为亚组，即4至6毫米或>6毫米。计算每个材料组和每个亚组在1年、3年和6年时的Kaplan-Meier生存估计值。(3) 结果：总共考虑了136例患者一期植入的289颗种植体。共记录了35例失败病例。异种移植物组1年时的总体生存率为94.2%，血凝块单独使用组为85.9%；3年时分别为91.1%和81.6%；6年时分别为91.1%和78.7%。(4) 结论：在RABH为4 - 6毫米的患者中，仅利用血凝块的无移植干预不如使用异种移植物的干预成功。当RABH较低时，应尽可能优先选择与移植材料相关的鼻窦底增高术。
